

Bangladesh Support for Pneumococcal Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Bangladesh			
2. Grant number: 18-BGD-12a-X /17-BGD-12b-A / 18-BGD-12a-A / 13-BGD-08a-Y			
3. Date of Decision Letter: 21 December 2017			
4. Date of the Partnership Framework Agreement: 24 June 2013			
5. Programme title: New Vaccine Support (NVS), Pneumococcal Routine			
6. Vaccine type: Pneumococcal			
7. Requested product presentation and formulation of vaccine: 2017 – Pneumococcal (PCV10), 2 dose(s) per vial, LIQUID 2018 – Pneumococcal (PCV10), 4 dose(s) per vial , LIQUID			
8. Programme duration¹: 2014 - 2018			
9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement)			
	2014-2017	2018	Total ²
Programme Budget (US\$)	128,151,000 ³	44,363,500	172,514,500
Fragility, Emergencies and Refugees policy (Gavi supported)			
	2017	2018	Total
Programme Budget (US\$)	1,391,000	412,000	1,803,000
10. Vaccine introduction grant (in US\$) / Product switch grant: A Vaccine Introduction Grant in the amount of US\$3,233,500 was disbursed on 14 July 2014. A Product Switch Grant will be subject to a separate communication in Q1 2018.			
11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement) ⁴			
Type of supplies to be purchased with Gavi funds in each year	2014-2017	2018	
Number of Pneumococcal vaccines doses		13,195,200	
Annual Amounts (US\$)	128,151,000 ⁵	44,363,500	

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

³ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

⁴ This is the amount that Gavi has approved.

⁵ This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

Fragility, Emergencies and Refugees policy (Gavi supported)

Type of supplies to be purchased with Gavi funds in each year	2017	2018
Number of Pneumococcal vaccines doses	412,400	122,400
Annual Amounts (US\$)	1,391,000	412,000

12. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.

13. Self-procurement: Not applicable

14. Co-financing obligations: Reference code: 18-BGD-12a-X-C

According to the co-financing policy, Bangladesh falls within the group Preparatory transition.

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2018
Number of vaccine doses	1,151,200
Number of AD syringes	1,156,900
Number of re-constitution syringes	
Number of safety boxes	12,750
Value of vaccine doses (US\$)	3,510,095
Total co-financing payments (US\$) (including freight)	3,584,000

Co-financing obligations for refugee population: Reference code: 17-BGD-12b-A-C / 18-BGD-12a-A-C

According to the co-financing policy, Bangladesh falls within the group Preparatory transition.

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2017	2018
Number of vaccine doses	31,200	10,800
Number of AD syringes	31,400	10,300
Number of re-constitution syringes		
Number of safety boxes	350	125
Value of vaccine doses (US\$)	94,345	32,641

Total co-financing payments (US\$) (including freight)	96,500	33,500
1. Operational support for campaigns: Not applicable		
2. Additional reporting requirements:		
Reports and other information	Due dates	
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May 2018	
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat	
3. Financial clarifications: Not applicable		
4. Other conditions: Not applicable		

Signed by,



On behalf of Gavi

Hind Khatib-Othman

Managing Director, Country Programmes

21 December 2017